Medical devices are routinely used in clinical environments that evolve faster than the time it takes a manufacturer to gain another FDA-cleared use. Off-label use is lawful and often clinically driven, but it is increasingly conflated with contraindicated use. These misunderstandings can expose patients, providers, and manufacturers to avoidable risk.

For MedTech and device leaders navigating today’s regulatory climate, the distinction is more than academic.

A device may be used responsibly in an off-label scenario based on clinical judgment or emerging evidence, but its safety and performance have not been fully evaluated for that application. Contraindications, by contrast, exist because evidence has already demonstrated that risk outweighs benefit.

This distinction is particularly important given that approximately 43% of medical devices fall into the FDA’s Class II category, where products are regulated for moderate risk and rely on special controls, labeling, and use conditions to ensure safety. For these devices, boundaries matter.

Off-label use carries unknowns; contraindicated use carries known challenges. Treating them as interchangeable undermines patient safety and weakens compliance and risk-management frameworks.

A Case Study in Intended Use: Doppler Ultrasound

Vascular Dopplers illustrate how easily off-label and contraindicated use can be confused. Doppler systems are Class II medical devices and are widely used as noninvasive diagnostic tools. Some manufacturers have issued explicit warnings that certain Doppler devices are intended solely for noninvasive use and should not be used subcutaneously or within a surgical field due to unacceptable infection risk.

In these cases, the concern is not that the use falls outside cleared indications, but that it violates established safety guidance. That is a contraindication, not an off-label extension.

At the same time, newer Doppler technologies have been specifically designed and FDA-cleared for use in surgical environments, including evaluation of intraoperative and subcutaneous blood flow within a sterile field. These systems incorporate design features intended to mitigate infection risk and workflow challenges, such as cordless operation and disposable components.

The contrast highlights an important regulatory reality: devices within the same category and risk class can have fundamentally different intended uses and safety profiles. Assuming functional equivalence across them can lead to inappropriate use and regulatory exposure.

FDA Guidance Reinforces the Boundary

The FDA’s finalization of guidance in early 2025 on communicating scientific information about off-label uses underscores this distinction. While the guidance affirms that off-label use remains lawful, it emphasizes the importance of evidence-based, non-misleading communication and clear acknowledgment of data limitations.

Notably, regulatory flexibility around off-label use does not extend to contraindicated scenarios. Known risks must be respected, not rationalized.

For clinicians, confusing off-label with contraindicated use increases the likelihood of preventable harm. For health systems, it elevates liability and compliance risk. For manufacturers, it raises questions around labeling clarity, post-market surveillance, and how devices are positioned and understood in real-world use.

In particular, Class II devices, often occupy a gray zone between familiarity and formality. Their widespread adoption can create complacency, even as their safe use depends on strict adherence to intended use and controls.

As device innovation accelerates and clinical applications expand, clarity becomes a competitive and regulatory advantage. Off-label use demands thoughtful judgment, documentation, and transparency. Contraindicated use should remain a firm boundary.

Blurring the two does not advance innovation or care delivery. It simply increases risk for patients and for the MedTech ecosystem.